Effects of Koumiss on Intestinal Immune Modulation in Immunosuppressed Rats

Qinyu Li, Chunjie Zhang, Tuya Xilin, Mingyue Ji, Xiangxi Meng, Yulian Zhao, Bateer Siqin, Na Zhang, Minhui LiFrontiers in Nutrition 2022 · DOI

Abstract

Koumiss is a traditional fermented dairy product with health and medicinal benefits, particularly popular in the Inner Mongolia Autonomous Region of China. While it is known to regulate the gastrointestinal environment and enhance immunity, systematic reports on its specific immune-modulating effects have been scarce. This study identifies 21 bioactive components in Koumiss using LC-MS/MS and evaluates their therapeutic effects in an immunosuppressed rat model. Results demonstrate that Koumiss corrects organ atrophy, restores peripheral blood lymphocyte counts, and improves small intestinal mucosal structure, providing a scientific basis for its use as a therapeutic product.

Introduction

Koumiss, a traditional fermented horse milk, has been a cornerstone of Mongolian medicine for centuries. It is traditionally used to treat a variety of ailments, including tuberculosis, scurvy, and chronic digestive disorders. Despite its widespread use and anecdotal success, the underlying pharmacological mechanisms—especially regarding immune modulation—remain poorly understood. This study sought to characterize the chemical profile of Koumiss and validate its immune-restorative properties through computational and in vivo models.

Figure 1: Traditional koumiss production process in the Xilinguole league of the Inner Mongolia Autonomous Region.

Methodology

The researchers employed a multi-disciplinary approach to investigate the therapeutic potential of Koumiss:

  1. Chemical Characterization: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) was used to identify the product's composition. By leveraging software like Compound Discoverer and libraries like mzCloud and ChemSpider, 21 key bioactive components were identified.
  2. Molecular Docking: Computational modeling (AutoDock Vina) was used to predict the interaction between these 21 compounds and critical immune targets, including TNF, HLA-DRB1, FKBP1A, IL10, and IL2. Structures were retrieved from the Protein Data Bank (PDB) and PubChem.
  3. Animal Model Validation: A Sprague-Dawley rat model was used, with immunosuppression induced by Cyclophosphamide (CY), a chemotherapy drug known to cause leukopenia and organ atrophy. Rats were treated with varying doses of Koumiss to observe recovery in organ indices, hematological markers, and intestinal histology.

Key Findings

Chemical and Computational Insights

The identification of 21 specific compounds, such as L-Tryptophan and Linolenic acid, provides a concrete "chemical map" of Koumiss. Molecular docking revealed that most of these compounds possess strong binding affinities (≤ -5.0 kcal/mol) for immune-related proteins. Notably, Progesterone showed high affinity for IL2 and IL10, suggesting these pathways may be central to Koumiss’s therapeutic action.

Physiological Restoration

The in vivo trials yielded several significant results:

  • Organ Recovery: Koumiss treatment significantly reversed the atrophy of the thymus and spleen, which are vital for immune cell maturation and surveillance.
  • Hematological Improvement: There was a marked increase in White Blood Cell (WBC) counts and the CD4+/CD8+ T-cell ratio in treated rats compared to the immunosuppressed control group, suggesting a sophisticated modulation of the adaptive immune response.
  • Intestinal Integrity: Koumiss effectively "rebuilt" the physical defense barrier of the gut. It increased the height of the intestinal villi and the number of Peyer’s patches—specialized lymphoid follicles essential for intestinal immune surveillance.

Conclusion and Future Directions

This study provides robust evidence that Koumiss acts as a potent immunomodulator. By restoring both the chemical signaling (cytokines and cell ratios) and the physical structure (intestinal mucosa) of the immune system, Koumiss offers a multi-faceted approach to treating immunosuppression.

While these results are promising, the authors acknowledge that future research should explore the role of the gut microbiome, as Koumiss is a probiotic-rich substance. Additionally, clinical trials are necessary to translate these findings from rat models to human therapeutic applications.

Summary updated

Abstract

Koumiss is a traditional fermented dairy product with health and medicinal benefits. It is very popular in the Inner Mongolia Autonomous Region of China. The results of relevant studies have shown that koumiss can regulate the gastrointestinal environment, improve the absorption of nutrients, improve the body's intolerance to lactose, enhance the body's immunity, prevent scurvy and atherosclerosis, and aid in the treatment of tuberculosis. However, there are no systematic reports on the effects of koumiss on immunity. In this study, we aimed to decipher the effects of koumiss on intestinal immune modulation. We used liquid chromatography-tandem mass spectrometry (LC-MS) analysis to determine the composition of Koumiss. Using Compound Discoverer software, we compared the mass spectrometry data with the compound information in the online databases ChemSpider and mzCloud to intelligently identify the main chemical components of koumiss. Additionally, we used Mass Frontier small molecule fragmentation library<sup>TM</sup> to determine the structure of fragment ions. A total of 21 components were identified, which clarified the chemical basis of koumiss. These 21 compounds were then used to perform molecular docking with immune-related targets, such as TNF, IL2, IL10, etc. The results indicated good docking activity between most of the compounds and the targets. Then, an immunosuppressive rat model was used to determine the therapeutic effect of koumiss. The results of this study showed that koumiss could, to a certain extent, correct the atrophy of the thymus and spleen in immunosuppressed model rats. The number of leukocytes, lymphocytes, and the CD4<sup>+</sup>/CD8<sup>+</sup> ratio of peripheral blood lymphocytes was also increased. In addition, it could effectively improve the structure of the small intestinal mucosa, which shows that koumiss has a positive effect on the intestinal immune function of immunosuppressed rats. These findings provide an experimental basis for the development and utilization of koumiss as a therapeutic product.
BibTeX
@inproceedings{li2022effects,
  author = {Qinyu Li and Chunjie Zhang and Tuya Xilin and Mingyue Ji and Xiangxi Meng and Yulian Zhao and Bateer Siqin and Na Zhang and Minhui Li},
  title = {{Effects of Koumiss on Intestinal Immune Modulation in Immunosuppressed Rats}},
  booktitle = {Frontiers in Nutrition},
  year = {2022},
  doi = {10.3389/fnut.2022.765499},
}
Figure